CA
NZ
UK
AU
IND
US
● Merck finished as the Dow's worst performer, with no confirmed company-specific news behind the decline.
● Moderna rallied sharply ahead of joining the Nasdaq-100 on Oct. 9, replacing Warner Bros. Discovery.
● Investors positioned ahead of Oct. 24 Phase 3 data on intismeran, Moderna's personalized cancerVaccinedeveloped with Merck.
● AbbVie and Genmab reported that their epcoritamab combination reduced the risk of disease progression or death in newly diagnosed lymphoma.
● Abbott rose with no confirmed company-specific news, part of a stronger showing from medical-device makers.
● Invisalign monthly active user growth slowed from July and was flat by September.
● Leerink Partners downgraded Bristol-Myers to Market Perform and cut its price target to $59 from $73.
● Life-science tools peers Thermo Fisher, Danaher and Illumina rallied alongside it.
AbbVie (NYSE:ABBV), the North Chicago, Illinois drugmaker behind Humira, Skyrizi and Rinvoq, is trading higher in Monday's session. The shares are up 1.20% at $265.98, outpacing a mixed group of large drugmakers, while a healthcare sector fund is up about 0.9% and the sector …
Alignment Healthcare (NASDAQ:ALHC), the Orange, California technology-driven Medicare Advantage insurer serving about 217,500 seniors across five states, is rebounding in Monday's session. The shares are up 6.39% at $8.45, extending last week's bounce from a brutal selloff.
Please wait processing your request...